Johnson & Johnson’s Rybrevant shows 45% response rate in HNSCC
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
This new facility strengthens Latin America as a collaborative hub
IKS Health's innovative solution orchestrates a roll out of critical operations functions into a unified and efficient connected workflow
Lutavit A/D3 1000/200 NXT provides a combination of vitamin A and vitamin D3 in one formulation
These findings follow positive Phase 3 results presented earlier this year
New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
The anatomage table is one of the most advanced 3D real-tissue–based anatomy visualization systems in the world
Datamatics will automate the Medication Administration Record process by integrating its intelligent automation products, TruBot and TruCap+
Subscribe To Our Newsletter & Stay Updated